Home Overview Press Room Blog Publications For Students about us
Search

About the States' Policies & Human Biotechnology


Individual states are filling the regulatory void created by the federal government’s failure to provide comprehensive legislation governing human biotechnologies. This is creating an often inconsistent policy patchwork.

California

State action is evident in a number of areas, including embryonic stem cell, cloning, egg retrieval, and assisted reproduction. More than a dozen states have laws banning reproductive cloning, about half of which also prohibit cloning for stem cell research. Dozens of similar bills are introduced in other states each year.

In response to President Bush’s restrictions on the federal funding of human embryonic stem cell research, several states initiated their own funded research programs. California led the way in 2004 with Proposition 71, which set aside $3 billion of public funds for stem cell research over ten years.



This scientist is trying to stop a lab-created global disasterby Kristen V. BrownFusionJune 27th, 2016Kevin Esvelt, one of the first scientists to realize CRISPR could be used in gene drives, calls himself a "critic of genetic engineering" and says, "If we misuse our power, we lose the trust. That is the tightrope we walk."
Eugenics victim still waiting for last paymentby Tim BucklandStar News OnlineJune 25th, 2016North Carolina's fund to compensate victims of its eugenic sterilization program is in limbo, with lawsuits pending.
All about the base: New businesses eye the opportunities in managing genome dataThe EconomistJune 25th, 2016Currently, one firm - Illumina - controls 70% of a market worth $3.3 billion in 2015.
They’re going to CRISPR people. What could possibly go wrong?by Sharon BegleySTATJune 23rd, 2016Possible consequences range from off-target alterations to conflicts of interest in the clinical trial.
23andMe Sells Data for Drug Searchby Antonio RegaladoMIT Technology ReviewJune 21st, 201623andMe is monetizing DNA rather the way Facebook makes money from our "likes." What’s more, it gets its customers to pay for the privilege.
Federal Oversight Group Has Complaints But Says Yes To CRISPR Trialby Alex LashXconomyJune 21st, 2016Despite worries about conflict of interest, an NIH committee voted to let researchers move ahead with a clinical trial that could be the first use of CRISPR-Cas9 in a human treatment.
Book Review: Discounted Life - The Price of Global Surrogacy in Indiaby Ëlo LuikBioNewsJune 20th, 2016Rudrappa locates surrogacy within the histories of politics and control as well as aspiration, nationalism and modernisation that the bodies of working-class Indian women have long been subjects of and subjected to.
Money Behind First CRISPR Test? It’s from Internet Billionaire Sean Parkerby Antonio RegaladoMIT Technology ReviewJune 20th, 2016Parker’s foundation is unusual because it says it will control patents on research it funds and even bring treatments to market.
DIY sperm test to hit the market this fallby Meghana KeshavanSTAT NewsJune 20th, 2016The semen centrifuge will calculate sperm count, but not sperm motility or other factors that affect fertility.
Do women who donate their eggs run a health risk?by Sandra G. BoodmanThe Washington PostJune 20th, 2016Health advocates say that donors are being falsely reassured that the process is safe, without being told that there is no definitive research.
Displaying 1-10 of 458  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760